Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 for Cutaneous Squamous Cell Carcinoma in Situ
NCT04844983Phase 2Completed
- Sponsor
- Sirnaomics
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of sirna-tgf-b1 + sirna-cox-2 in cutaneous squamous cell carcinoma in situ (SCCIS), sponsored by Sirnaomics. Started May 2021; status: completed.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
cutaneous squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on NCT04844983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844983.